Therapy of Superficial Bladder Carcinomas

Otto, T.; Krege, Susanne; Noll, F.; Rübben, H.

doi:10.1159/000030416

Cited by 5 publications

(3 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Superficial urothelial cell carcinoma of the bladder encompasses a wide spectrum of recurrence or progression risks. The consensus of an aggressive treatment, including exanterative procedure, in high‐risk superficial bladder cancer (T1/G3 and in situ tumors) has been established 1, 2. However, concerning the other superficial bladder tumors, the classical histopathological markers do not define risk profiles and consequently there are no optimal treatment approaches and follow‐up schedules 3.…”

mentioning

confidence: 99%

Ki‐67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification

Santos

Amaro

Costa

et al. 2003

Intl Journal of Cancer

View full text Add to dashboard Cite

Approximately 80% of bladder tumors are urothelial superficial papillary carcinomas (USPC). Despite a generally good prognosis, these tumors have a strong propensity to recur and about 1/3 of them compared to disease progression. Histological assessment of these superficial tumors is not sufficiently discriminator in predicting prognosis; therefore, we decided to evaluate the prognostic significance of p53 and Ki-67 immunoexpression in low-grade (GI-II) USPC in order to predict the potential outcome of these tumors. P53 and Ki-67 immunoexpression were studied in function of recurrence-free and progression-free survival in 159 primary superficial bladder tumors. A prognostic risk model based on grade, stage and multifocality was also evaluated. P53 accumulation was significantly related to tumor progression (p‫.)600.0؍‬ High Ki-67 index (>18%) and multifocality were significantly related to recurrence (both p‫)1000.0؍‬ and progression-free survival (both p‫)1000.0؍‬ and were independent prognostic factors in the multivariate analysis. The prognostic risk model based on grade, stage and multifocality was not an efficient discriminator of outcome. Adding the Ki-67 index into the risk model, single pTa/T1-GI Ki-67 positive tumors, usually classified as low risk, were reclassified as of intermediate risk. After this reclassification, the risk group model identified a subgroup of pTa/T1-G1 with a high risk of recurrence and progression. Ki-67 index is a reliable prognostic marker in urothelial superficial bladder carcinoma and, when included into a risk profile classification of the low-grade USPC, the accuracy of the prognostic discrimination is enhanced.

show abstract

mentioning

confidence: 99%

Ki‐67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification

Santos

Amaro

Costa

et al. 2003

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…At present, superficial bladder cancer is stratified by differentiation grade and stage into three groups of different risk profiles (Ta G1-2 vs. T1 G1-2 vs. Tis/T1 G3). At present, the standard therapy is fractionated transurethral resection ( 1 ). Although the rate of mortality with this therapy is low, the recurrence rates are 50–70%, of which 10–20% cases develop into muscle-infiltration bladder cancer, and the five-year survival rate was less than 50% ( 2 – 6 ).…”

Section: Introductionmentioning

confidence: 99%

Biological effects of eukaryotic recombinant plasmid pReceiver-M61-BAI-1 transfection on T24 cells and HUVECs

Tian

Sun

et al. 2016

Molecular Medicine Reports

View full text Add to dashboard Cite

The aim of the current study was to investigate the biological effect on T24 cells and human umbilical vein endothelial cells (HUVECs) of transfection with brain-specific angiogenesis inhibitor-1 (BAI-1). The recombinant plasmid pReceiver-M61-BAI-1 was transfected into human superficial bladder tumor cells (T24) and HUVECs, in parallel with the vector control. mRNA and protein expression levels of BAI-1 were then detected by quantitative polymerase chain reaction (qPCR) and western blotting, respectively. Cell apoptosis of T24 cells and HUVECs prior and subsequent to transfection with BAI-1 was analyzed by flow cytometric analysis. Proliferation of T24 cells and HUVECs prior and subsequent to transfection of BAI-1 was assessed by the MTT method. T24 cells and HUVECs transfected with pReceiver-M61-BA1-1 were classed as the experimental group; T24 cells and HUVECs transfected with p-Receiver-M61 were the control group. qPCR and western blotting methods confirmed that there was positive expression of BAI-1 in T24 cells and HUVECs transfected with pReceiver-M61-BAI-1, however BAI-1 was not expressed in T24 cells and HUVECs transfected with pReceiver-M61. The results of the MTT assay demonstrated that absorbance was markedly reduced in HUVECs at 12, 48 and 72 h subsequent to transfection with pReceiver-M61-BAI-1 when compared with that of the control group and in T24 cells transfected with p-Receiver-M61-BAI-1. Furthermore, flow cytometry results also indicated that the apoptotic rate of HUVECs transfected with p-Receiver-M61-BAI-1 was significantly increased compared with that of the control group and T24 cells transfected with p-Receiver-M61-BAI-1. BAI-1 was observed to markedly inhibit the proliferation of vascular endothelial cells in vitro, however, no direct inhibition by BAI-1 was observed in T24 cells. In conclusion, BAI-1 is suggested to be a potential novel therapautic target for the inhibition of tumor neovascularization.

show abstract

“…About 75-85% of patients initially present with non-muscle-invasive bladder cancer (NMIBC; stages T a , CIS, T 1 ) [3]. Transurethral resection of bladder tumor (TUR-BT) is the main method for the management of NMIBC [4]. …”

Section: Introductionmentioning

confidence: 99%

Tumor Suppressor in Lung Cancer-1 Is a Prognostic Predictor for the Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer

Chen

Yang²,

Liu³

et al. 2015

Urol Int

View full text Add to dashboard Cite

Objective: To investigate the relationship between the expression of tumor suppressor in lung cancer-1 (TSLC1) and clinicopathological characteristics of patients with non-muscle-invasive bladder cancer (NMIBC) and evaluate the prognostic significance of TSLC1. Methods: TSLC1 expression in 241 specimens of NMIBC was examined by immunohistochemistry. The correlation between TSLC1 expression and clinicopathological characteristics was evaluated using the chi-square test. The prognostic significance of TSLC1 was analyzed by univariate, multivariate analysis and Kaplan-Meier survival curves. Results: The total negative rate of TSLC1 expression was 47.3% in NMIBC. Decreased expression of TSLC1 was correlated with a higher clinical stage, higher pathological grade, the number of tumors, lager tumor size, tumor recurrence and progression. TSLC1 expression was an independent risk factor for predicting tumor recurrence (p = 0.005) and progression (p < 0.001). Conclusion: Decreased expression of TSLC1 is correlated with the malignancy of NMIBC tissues and low TSLC1 expression may serve as a predictor for bladder cancer recurrence and progression.

show abstract

Therapy of Superficial Bladder Carcinomas

Cited by 5 publications

References 37 publications

Ki‐67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification

Ki‐67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification

Biological effects of eukaryotic recombinant plasmid pReceiver-M61-BAI-1 transfection on T24 cells and HUVECs

Tumor Suppressor in Lung Cancer-1 Is a Prognostic Predictor for the Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer

Contact Info

Product

Resources

About